- Report
- June 2026
- 195 Pages
Global
From €3207EUR$3,545USD£2,746GBP
€3563EUR$3,939USD£3,052GBP
- Report
- July 2025
- 150 Pages
Global
From €4388EUR$4,850USD£3,757GBP
- Report
- March 2026
- 170 Pages
United States
From €4388EUR$4,850USD£3,757GBP
- Report
- February 2026
- 250 Pages
Global
From €4062EUR$4,490USD£3,478GBP
- Report
- April 2026
- 160 Pages
Global
From €3003EUR$3,320USD£2,572GBP
€3754EUR$4,150USD£3,215GBP
- Report
- April 2023
- 147 Pages
Global
From €4477EUR$4,949USD£3,834GBP
- Report
- May 2024
- 128 Pages
Global
From €3618EUR$3,999USD£3,098GBP
- Report
- September 2024
- 250 Pages
Global
From €4477EUR$4,949USD£3,834GBP
- Report
- March 2026
- 153 Pages
Canada
From €4388EUR$4,850USD£3,757GBP
- Report
- March 2026
- 162 Pages
China
From €4388EUR$4,850USD£3,757GBP
- Report
- March 2026
- 154 Pages
Germany
From €4388EUR$4,850USD£3,757GBP
- Report
- March 2026
- 155 Pages
India
From €4388EUR$4,850USD£3,757GBP

Acetazolamide is a medication used in the treatment of cardiovascular diseases. It is a carbonic anhydrase inhibitor, which works by decreasing the production of bicarbonate in the body, thus reducing the amount of fluid in the blood vessels. This helps to reduce the pressure in the vessels, which can help to reduce the risk of stroke, heart attack, and other cardiovascular events. Acetazolamide is also used to treat glaucoma, epilepsy, and altitude sickness.
Acetazolamide is available in both generic and brand-name forms. It is typically taken orally, but can also be administered intravenously. Common side effects include nausea, vomiting, and dizziness.
The acetazolamide market is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more